The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Alpha-synuclein Toxicity in LRRK2 Pre-clinical Models and Rescue by LRRK2 Silencing
Study Rationale:
Genetic mutations that alter the function of the LRRK2 protein increase the risk of developing a form of Parkinson's disease (PD). Age and other environmental factors combine with... -
Biomarkers Across Neurodegenerative Diseases, 2016Seeds of Dementia: Misfolded Proteins in Neurodegenerative Disorders
Study Rationale:
Alzheimer's disease (AD), Lewy Body Dementia (LBD) and frontotemporal dementia (FTD) are characterized by the accumulation of specific proteins in the brain. The identification of...
-
Target Advancement Program, 2016Role of GTPase Activity in Neurodegenerative Phenotypes Induced by G2019S LRRK2 in a Pre-clinical Model of Parkinson’s Disease
Study Rationale:
Mutations in the LRRK2 gene cause familial (inherited) Parkinson's disease (PD). Familial mutations tend to lead to increased kinase (protein regulation) activity or impaired GTPase... -
Target Advancement Program, 2016Validation of a Protein, Transglutaminase 2, as a Way to Reduce Alpha-synuclein Clumping and Toxicity in Parkinson's Disease
Study Rationale:
Accumulation of abnormal aggregates (clumps) of the protein alpha-synuclein is a key feature of Parkinson's disease (PD) and plays a role in neuron degeneration (cell loss)...
-
Research Grant, 2016Further Validation of SIRT3 in a Parkinsonian Model
Objective/Rationale:
Dysfunctional mitochondria (powerhouses of the cell) are central to the pathology of Parkinson's Disease (PD). Sirtuins are a group of proteins that increase energetic processes... -
Research Grant, 2016Validation of Uncharacterized LRRK2 Phosphorylation Sites
Study Rationale:
The Parkinson's disease (PD) protein kinase (enzyme) LRRK2 is regulated by a chemical process called phosphorylation. To date, only a handful of the sites of phosphorylation have been...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.